- Home
- PGY vs VRDN Comparison
PGY vs VRDN Comparison
Compare PGY & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGY
- VRDN
- Stock Information
- Founded
- PGY 2016
- VRDN 2006
- Country
- PGY United States
- VRDN United States
- Employees
- PGY N/A
- VRDN N/A
- Industry
- PGY Finance: Consumer Services
- VRDN Medical Specialities
- Sector
- PGY Finance
- VRDN Health Care
- Exchange
- PGY Nasdaq
- VRDN Nasdaq
- Market Cap
- PGY 2.6B
- VRDN 2.1B
- IPO Year
- PGY N/A
- VRDN N/A
- Fundamental
- Price
- PGY $24.39
- VRDN $28.99
- Analyst Decision
- PGY Strong Buy
- VRDN Strong Buy
- Analyst Count
- PGY 7
- VRDN 11
- Target Price
- PGY $39.86
- VRDN $39.60
- AVG Volume (30 Days)
- PGY 4.6M
- VRDN 1.9M
- Earning Date
- PGY 11-10-2025
- VRDN 11-05-2025
- Dividend Yield
- PGY N/A
- VRDN N/A
- EPS Growth
- PGY N/A
- VRDN N/A
- EPS
- PGY N/A
- VRDN N/A
- Revenue
- PGY $1,245,946,000.00
- VRDN $70,789,000.00
- Revenue This Year
- PGY $27.88
- VRDN N/A
- Revenue Next Year
- PGY $16.36
- VRDN $37,670.06
- P/E Ratio
- PGY N/A
- VRDN N/A
- Revenue Growth
- PGY 28.33
- VRDN 23340.07
- 52 Week Low
- PGY $8.20
- VRDN $9.90
- 52 Week High
- PGY $44.99
- VRDN $29.27
- Technical
- Relative Strength Index (RSI)
- PGY 40.74
- VRDN 75.13
- Support Level
- PGY $22.76
- VRDN $22.14
- Resistance Level
- PGY $29.75
- VRDN $28.60
- Average True Range (ATR)
- PGY 1.89
- VRDN 1.29
- MACD
- PGY 0.02
- VRDN 0.43
- Stochastic Oscillator
- PGY 32.27
- VRDN 97.41
About PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).